Literature DB >> 31112757

Delay expression of NKp30 on NK cells correlates with long-term mycophenolate mofetil treatment and higher EBV viremia post allogenic hematological stem cells transplantation.

Xing-Xing Yu1, Xun-Hong Cao2, Hong Yan2, Xue-Yi Luo2, Xiao-Su Zhao2, Yu-Qian Sun2, Yu Wang2, Lan-Ping Xu2, Xiao-Hui Zhang2, Ying-Jun Chang2, Xiao-Jun Huang1, Xiang-Yu Zhao3.   

Abstract

Mycophenolate mofetil (MMF) is an immunosuppressive agent that is widely used in graft-versus-host disease prophylaxis because of its inhibitory function on T cells and B cells. However, the effect of MMF on natural killer cell reconstitution after allogenic hematological transplantation is largely unknown. The present study examined the effects of different MMF administration durations after haploidentical allo-HSCT on NK cell reconstitution. Ninety patients were enrolled in this study and defined into two groups in term of MMF duration. We found that MMF patients in the long-term MMF group were associated with a poor reconstitution of NK cells and a significantly lower cytotoxicity from day 30 to day 180 post-transplantation. Especially, the long-term MMF group inhibits reconstitution of NKp30 NK subsets, which correlated with higher risk of EBV viremia. Multivariate analysis showed that a better reconstitution of NKp30 cells was associated with lower EBV viremia (HR0.957, p = .04). In vitro experiments demonstrated that the active metabolite of MMF, mycophenolic acid (MPA), inhibited the proliferation and cytotoxicity of NK cells from healthy donors or patients at day 30 post-transplantation. In summary, our findings demonstrated that long-term MMF administration delayed the quality and quantity of NK cells, especially NKp30 subpopulations, which was associated with decreased EBV viremia post allogeneic HSCT.
Copyright © 2019 Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Allo-HSCT; MMF; NK cells; NKp30; Reconstitution

Year:  2019        PMID: 31112757     DOI: 10.1016/j.clim.2019.05.010

Source DB:  PubMed          Journal:  Clin Immunol        ISSN: 1521-6616            Impact factor:   3.969


  2 in total

1.  Immunosuppressant indulges EBV reactivation and related lymphoproliferative disease by inhibiting Vδ2+ T cells activities after hematopoietic transplantation for blood malignancies.

Authors:  Jiangying Liu; Haitao Gao; Lan-Ping Xu; Xiao-Dong Mo; Ruoyang Liu; Shuang Liang; Ning Wu; Ming Wang; Zhidong Wang; Ying-Jun Chang; Yu Wang; Xiao-Hui Zhang; Xiao-Jun Huang
Journal:  J Immunother Cancer       Date:  2020-03       Impact factor: 13.751

Review 2.  Factors Associated with Post-Transplant Active Epstein-Barr Virus Infection and Lymphoproliferative Disease in Hematopoietic Stem Cell Transplant Recipients: A Systematic Review and Meta-Analysis.

Authors:  Pascal Roland Enok Bonong; Monica Zahreddine; Chantal Buteau; Michel Duval; Louise Laporte; Jacques Lacroix; Caroline Alfieri; Helen Trottier
Journal:  Vaccines (Basel)       Date:  2021-03-19
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.